Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis | Zendy

W. Marc | Zendy; Debra Benator | Zendy; Charles A. Peloquin | Zendy; W. J. Burman | Zendy; Andrew Ver | Zendy; Melissa Engle | Zendy; Abdul Qadir Khan | Zendy; Zhen Zhao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the Drug Interaction between Rifabutin and Efavirenz in Patients with HIV Infection and Tuberculosis

Author(s) -

W. Marc,

Debra Benator,

Charles A. Peloquin,

W. J. Burman,

Andrew Ver,

Melissa Engle,

Abdul Qadir Khan,

Zhen Zhao

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/496980

Subject(s) - rifabutin , efavirenz , medicine , isoniazid , pharmacokinetics , gastroenterology , pharmacology , interquartile range , tuberculosis , immunology , viral load , antiretroviral therapy , human immunodeficiency virus (hiv) , pathology , clarithromycin , helicobacter pylori

Because of drug-drug interactions mediated by hepatic cytochrome P450, tuberculosis treatment guidelines recommend an increase in rifabutin from 300 mg to 450 or 600 mg when combined with efavirenz-based antiretroviral therapy. To assess this recommendation, rifabutin and efavirenz pharmacokinetic parameters were investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research